Ocular Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OCL022 MIFTS: 55	Ocular Melanoma Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma ¹² ⁷⁷ ⁵⁴ ⁵⁶ ¹⁵ ¹⁷

Intraocular Melanoma ¹² ⁵⁴ ³⁰ ⁶

Malignant Melanoma of Eye ⁷⁴

Melanoma of the Uvea ⁵⁴

Melanoma of Eye ¹²

Uveal Melanoma ⁵⁴

Eye Melanoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Eye diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1752

EFO ¹⁷ EFO_1000403

UMLS ⁷⁴ C0558356

Sources

Summaries for Ocular Melanoma

NIH Rare Diseases : ⁵⁴ Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract. The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors.

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to tumor predisposition syndrome and melanoma. An important gene associated with Ocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are Human cytomegalovirus infection and Ras signaling pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : ¹² An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : ⁷⁷ Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Sources

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)

#	Related Disease	Score	Top Affiliating Genes
1	tumor predisposition syndrome	32.8	BAP1 BRCA2
2	melanoma	31.0	CDKN2A MAGEA1 MAGEA3 MC1R NRAS
3	macular dystrophy, dominant cystoid	30.0	SERPINF1 VEGFA
4	malignant peritoneal mesothelioma	30.0	BAP1 CDKN2A
5	dysplastic nevus syndrome	29.9	BRCA2 CDKN2A
6	malignant conjunctival melanoma	29.4	GNA11 GNAQ NRAS
7	melanoma, uveal	28.5	BAP1 CDKN2A GNA11 GNAQ MAGEA1 MC1R
8	melanoma, cutaneous malignant 1	28.3	BAP1 CDKN2A GNA11 GNAQ KIT MC1R
9	posterior uveal melanoma	12.5
10	necrotic uveal melanoma	12.4
11	mixed cell uveal melanoma	12.4
12	spindle cell intraocular melanoma	12.3
13	uveal epithelioid cell melanoma	11.4
14	bap1 tumor predisposition syndrome	11.4
15	iris spindle cell melanoma	11.3
16	maxillary sinus adenoid cystic carcinoma	10.4	IL2 KIT
17	macular retinal edema	10.3
18	ovarian melanoma	10.3	KIT NRAS
19	conventional fibrosarcoma	10.3	KIT NRAS
20	malignant spindle cell melanoma	10.3	KIT NRAS
21	adenoid basal cell carcinoma	10.2	CDKN2A KIT
22	neovascular glaucoma	10.2
23	myotonic dystrophy	10.2
24	myotonia atrophica	10.2
25	peritoneum cancer	10.2	BAP1 BRCA2
26	lymphoepithelioma-like thymic carcinoma	10.2	CDKN2A KIT
27	glycogen-rich clear cell breast carcinoma	10.2	BRCA2 CDKN2A
28	depression	10.2
29	skin melanoma	10.2
30	balanoposthitis	10.2	CDKN2A IL2
31	breast giant fibroadenoma	10.2	BRCA2 CDKN2A
32	infiltrating angiolipoma	10.2	CDKN2A VEGFA
33	anxiety	10.1
34	herpes simplex	10.1
35	hypoxia	10.1
36	cervicitis	10.1	CDKN2A IL2
37	balanitis xerotica obliterans	10.1	CDKN2A VEGFA
38	acral lentiginous melanoma	10.1	CDKN2A KIT NRAS
39	melanoma metastasis	10.1
40	insulin-like growth factor i	10.0
41	hemangioma	10.0
42	uveitis	10.0
43	optic nerve disease	10.0
44	neuropathy	10.0
45	female reproductive system disease	10.0	BRCA2 CDKN2A VEGFA
46	reproductive system disease	10.0	BRCA2 CDKN2A VEGFA
47	melanocytic nevus syndrome, congenital	10.0	MC1R NRAS
48	pharynx cancer	10.0	CDKN2A KIT VEGFA
49	endocrine gland cancer	10.0	BRCA2 CDKN2A VEGFA
50	gastrointestinal system cancer	10.0	CDKN2A KIT VEGFA

Graphical network of the top 20 diseases related to Ocular Melanoma:

Sources

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

⁴⁷ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.29	BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
2	endocrine/exocrine gland	MP:0005379	10.28	BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
3	immune system	MP:0005387	10.26	BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
4	behavior/neurological	MP:0005386	10.23	BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
5	cardiovascular system	MP:0005385	10.22	BAP1 CDKN2A GNA11 GNAQ IL2 KIT
6	growth/size/body region	MP:0005378	10.22	BAP1 BRCA2 CDKN2A GNA11 GNAQ IL2
7	homeostasis/metabolism	MP:0005376	10.19	BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
8	digestive/alimentary	MP:0005381	10.15	BAP1 BRCA2 CDKN2A IL2 KIT NRAS
9	integument	MP:0010771	10.11	BAP1 BRCA2 CDKN2A GNA11 GNAQ KIT
10	craniofacial	MP:0005382	10.03	GNA11 GNAQ KIT MC1R NRAS VEGFA
11	limbs/digits/tail	MP:0005371	9.98	BRCA2 GNA11 GNAQ KIT MC1R NRAS
12	neoplasm	MP:0002006	9.97	BAP1 BRCA2 CDKN2A IL2 KIT MC1R
13	liver/biliary system	MP:0005370	9.88	CDKN2A GNA11 IL2 KIT NRAS VEGFA
14	no phenotypic analysis	MP:0003012	9.87	BAP1 CDKN2A IL2 KIT MC1R NRAS
15	normal	MP:0002873	9.86	BRCA2 CIITA GNA11 GNAQ KIT NRAS
16	pigmentation	MP:0001186	9.7	CDKN2A GNA11 GNAQ KIT MC1R NRAS
17	respiratory system	MP:0005388	9.5	BAP1 CDKN2A GNA11 GNAQ IL2 KIT
18	skeleton	MP:0005390	9.28	BRCA2 CDKN2A CIITA GNA11 GNAQ KIT

Sources

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ranibizumab

Approved

Phase 4,Phase 2,Phase 3

347396-82-1

459903

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

124-94-7

31307

Angiogenesis Modulating Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

glucocorticoids

Phase 4,Phase 2,Phase 3,Not Applicable

Anti-Inflammatory Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Hormone Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Triamcinolone hexacetonide

Phase 4,Phase 2,Phase 3,Not Applicable

Hormones

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Triamcinolone diacetate

Phase 4,Phase 2,Phase 3,Not Applicable

Immunologic Factors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

triamcinolone acetonide

Phase 4,Phase 2,Phase 3,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Dacarbazine

Approved, Investigational

Phase 3,Phase 2

4342-03-4

5351166

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Not Applicable

216974-75-3

Melphalan

Approved

Phase 3,Phase 2

148-82-3

460612 4053

Fotemustine

Investigational

Phase 3

92118-27-9

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1,Early Phase 1

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Immunological

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Vaccines

Phase 3,Phase 2,Phase 1,Not Applicable

Mitogens

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2

Gemcitabine

Approved

Phase 2,Phase 1

95058-81-4

60750

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Cisplatin

Approved

Phase 2,Phase 1

15663-27-1

2767 441203 84093

Sodium Citrate

Approved, Investigational

Phase 2

68-04-2

Sunitinib

Approved, Investigational

Phase 2,Phase 1

557795-19-4, 341031-54-7

5329102

Temozolomide

Approved, Investigational

Phase 2,Phase 1

85622-93-1

5394

Sorafenib

Approved, Investigational

Phase 2,Phase 1

284461-73-0

216239 406563

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Ipilimumab

Approved

Phase 2,Phase 1,Early Phase 1

477202-00-9

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Trametinib

Approved

Phase 2,Phase 1

871700-17-3

11707110

Sirolimus

Approved, Investigational

Phase 2,Not Applicable

53123-88-9

46835353 5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Pasireotide

Approved

Phase 2

396091-73-9

9941444

Somatostatin

Approved, Investigational

Phase 2,Phase 1

38916-34-6, 51110-01-1

53481605

Everolimus

Approved

Phase 2,Not Applicable

159351-69-6

70789204 6442177

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Sargramostim

Approved, Investigational

Phase 2,Phase 1

123774-72-1, 83869-56-1

Ethiodized oil

Approved, Investigational

Phase 2

8008-53-5

Peginterferon alfa-2b

Approved

Phase 2

215647-85-1, 99210-65-8

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Aluminum sulfate

Approved

Phase 2

10043-01-3

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

Interventional clinical trials:

(show top 50) (show all 171)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy	Unknown status	NCT00540930	Phase 4	Ranibizumab
2	TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy	Unknown status	NCT02379000	Phase 4	Triamcinolone Acetonide
3	Collaborative Ocular Melanoma Study (COMS)	Unknown status	NCT00000124	Phase 3
4	Treatment Of Radiation Retinopathy Trial	Unknown status	NCT00811200	Phase 2, Phase 3	ranibizumab;triamcinolone acetonide
5	Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)	Completed	NCT01974752	Phase 3	75mg selumetinib;placebo;Dacarbazine
6	Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma	Completed	NCT00324727	Phase 3	melphalan;regional chemotherapy;systemic chemotherapy
7	Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma	Recruiting	NCT02678572	Phase 3
8	Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma	Recruiting	NCT01983748	Phase 3
9	The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases	Recruiting	NCT01785316	Phase 3
10	Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma	Active, not recruiting	NCT02843386	Phase 3	Adjuvant chemotherapy by Fotemustin
11	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Not yet recruiting	NCT03172299	Phase 3	Aflibercept Injection;False injection
12	Vaccine Therapy in Treating Patients With Melanoma of the Eye	Terminated	NCT00036816	Phase 3
13	Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma	Terminated	NCT00110123	Phase 3	fotemustine;isolated perfusion
14	Study of Metastatic Ocular Melanoma	Unknown status	NCT00168870	Phase 2	Gemcitabine;Treosulfan
15	Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma	Unknown status	NCT00489944	Phase 2	cisplatin;sunitinib malate;tamoxifen citrate
16	Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye	Unknown status	NCT01217398	Phase 2	temozolomide
17	Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis	Unknown status	NCT02936388	Phase 2
18	A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma	Unknown status	NCT01377025	Phase 2	Placebo;Sorafenib;Sorafenib
19	A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma	Unknown status	NCT01551459	Phase 2	Dacarbazine;Sunitinib
20	STA-9090(Ganetespib) in Metastatic Ocular Melanoma	Completed	NCT01200238	Phase 2	STA-9090
21	Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma	Completed	NCT00109005	Phase 2	Revlimid
22	THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease	Completed	NCT01355120	Phase 2	Ipilimumab
23	A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma	Completed	NCT00062933	Phase 2
24	Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT00020475	Phase 2	gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
25	Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma	Completed	NCT00003802	Phase 2	pyrazoloacridine
26	Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma	Completed	NCT00085306	Phase 2
27	Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT01143402	Phase 2	Dacarbazine;Selumetinib;Temozolomide
28	Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT01413191	Phase 2
29	Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye	Completed	NCT00329641	Phase 2	carboplatin;paclitaxel;sorafenib tosylate
30	Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery	Completed	NCT00738361	Phase 2	nab-paclitaxel
31	Taxoprexin® Treatment for Advanced Eye Melanoma	Completed	NCT00244816	Phase 2	Taxoprexin
32	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	Completed	NCT01979523	Phase 2	Trametinib;Uprosertib
33	Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma	Completed	NCT01034787	Phase 2	CP-675,206
34	RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma	Completed	NCT01252251	Phase 2	RAD001 (Everolimus) and Pasireotide (SOM230) LAR
35	Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma	Completed	NCT00506142	Phase 2	Marqibo® (vincristine sulfate liposomes injection)
36	Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance	Completed	NCT01100528	Phase 2	dacarbazine
37	Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma	Completed	NCT02363283	Phase 2	Glembatumumab Vedotin
38	Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination	Completed	NCT02517736	Phase 2	Sorafenib at a dose of 800 mg / day
39	Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF	Completed	NCT00661622	Phase 2	GM-CSF
40	Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma	Completed	NCT00003339	Phase 2
41	Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma	Completed	NCT00084656	Phase 2
42	Vaccine Therapy in Treating Patients With Metastatic Melanoma	Completed	NCT00334776	Phase 2
43	PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma	Completed	NCT00238329	Phase 2	thalidomide
44	Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma	Completed	NCT00027742	Phase 2	temozolomide
45	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery	Completed	NCT00089206	Phase 2
46	Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma	Completed	NCT00089219	Phase 1, Phase 2
47	Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma	Completed	NCT00072345	Phase 2	lomustine;temozolomide;thalidomide
48	Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma	Completed	NCT00032045	Phase 2
49	Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma	Completed	NCT00031733	Phase 2	alum adjuvant
50	Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma	Completed	NCT00005815	Phase 1, Phase 2	temozolomide;thalidomide

Search NIH Clinical Center for Ocular Melanoma

Sources

Genetic Tests for Ocular Melanoma

Genetic tests related to Ocular Melanoma:

#	Genetic test	Affiliating Genes
1	Intraocular Melanoma ³⁰

Sources

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

⁴²

Eye, Liver, Retina, Skin, Testes, Bone, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

²⁰

The Eye

Sources

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 413)

#	Title	Authors	Year
1	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. ( 30924738 )	Arzu Ya?ar H...Urun Y	2019
2	Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. ( 30797699 )	Dean MK...Samuels SE	2019
3	Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. ( 30767147 )	Meijer TS...Vahrmeijer AL	2019
4	Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )	Bozkurt TK...Miller KM	2018
5	Headache with Aura: A case report of ocular melanoma. ( 30135025 )	Hackett A...Borden N	2018
6	Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. ( 30671022 )	Ashur-Fabian O...Fabian ID	2018
7	Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanoma? ( 30566923 )	Slopsema RL...Dagan R	2018
8	The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation. ( 30320098 )	Afshar AR...Damato BE	2018
9	Is Collaborative Ocular Melanoma Study (COMS) still relevant? ( 30249817 )	Honavar SG	2018
10	Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases. ( 30134646 )	Anastasiadis S...Katsinelos P	2018
11	Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )	Boone BA...Pingpank JF	2018
12	Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study. ( 29707895 )	Kanavi MR...Ahmadieh H	2018
13	MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. ( 28818442 )	Zoberi JE...Grigsby PW	2018
14	Visualization and Quantitative 3D Analysis of Intraocular Melanoma and Its Vascularization in a Hamster Eye. ( 29364141 )	Leszczy?ski B...Elas M	2018
15	Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )	Rostas JW...Martin RCG	2017
16	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )	Wei W...Knopp MV	2017
17	PRL-3/PTP4A3 phosphatase regulates integrin β1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )	Foy M...Planque N	2017
18	Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )	Iskanderani O...Roberge D	2017
19	Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )	Mahendraraj K...Chamberlain RS	2017
20	Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )	Blackman CF	2017
21	Tumor-specific frequencies and ocular melanoma. ( 27552371 )	Milham S...Stetzer D	2017
22	Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma. ( 28520637 )	Furdova A...Gregus M	2017
23	Imaging of ocular melanoma metastasis. ( 27168029 )	Balasubramanya R...O'Kane P	2016
24	Metastatic melanoma after 23 years of primary ocular melanoma. ( 27881589 )	Karde SR...Arockiam S	2016
25	Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )	Ahmed OA...Kelly C	2016
26	EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )	Vodencarevic AN...Sinanovic M	2016
27	A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )	Maleka A...Ullenhag GJ	2016
28	Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. ( 27476775 )	Grossniklaus HE...Coupland SE	2016
29	Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )	Johnson JE...Furutani KM	2016
30	Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )	Hartsell WF...Pankuch M	2016
31	Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )	Kilian MM...Loeffler KU	2016
32	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )	Yang H...Grossniklaus HE	2016
33	Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma. ( 25658144 )	Kilian MM...Herwig MC	2016
34	Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )	Kiparakis M...Chalkiadakis G	2015
35	A challenging case of ocular melanoma. ( 26429178 )	Costache M...C?rstoiu MM	2015
36	Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )	Park SJ...Park KH	2015
37	Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )	Fabian ID...Ashur-Fabian O	2015
38	Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )	Jiang X...Erb-Eigner K	2015
39	Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )	Foti PV...Ettorre GC	2015
40	Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )	Deufel CL...Furutani KM	2015
41	Inhibition of tumor growth by β-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model. ( 25405459 )	Shi H...Chen L	2015
42	Cost-effectiveness of proton beam therapy for intraocular melanoma. ( 25993284 )	Moriarty JP...Shah ND	2015
43	Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma. ( 24222710 )	Farah J...Clairand I	2014
44	Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. ( 24141377 )	Olofsson R...Lindn?r P	2014
45	Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )	Keshazare Sh...S Rasouli F	2014
46	Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )	Stedman B	2014
47	Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )	Zimmermann LW...Wilkinson DA	2014
48	Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )	Martorano LM...Campbell SM	2014
49	Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )	Grossniklaus HE	2013
50	The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )	Lund RW	2013

Sources

Genes for Ocular Melanoma

Genes related to Ocular Melanoma (2 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	GNAQ	G Protein Subunit Alpha Q	Protein Coding	416.63	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
2	GNA11	G Protein Subunit Alpha 11	Protein Coding	405.62	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
3	MC1R	Melanocortin 1 Receptor	Protein Coding	26.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12883368
4	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	22.81	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12385017
5	BAP1	BRCA1 Associated Protein 1	Protein Coding	21.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	IL2	Interleukin 2	Protein Coding	21.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	21.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	20.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	20.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	20.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CIITA	Class II Major Histocompatibility Complex Transactivator	Protein Coding	19.89	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15326139
12	PDCD6	Programmed Cell Death 6	Protein Coding	19.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15336963
13	MAGEA3	MAGE Family Member A3	Protein Coding	17.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	9220316
14	MAGEA1	MAGE Family Member A1	Protein Coding	17.55	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	9220316
15	SERPINF1	Serpin Family F Member 1	Protein Coding	16.75	GeneCards inferred via : Publications (show sections)

Sources

Variations for Ocular Melanoma

ClinVar genetic disease variations for Ocular Melanoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	GNAQ	NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913492	GRCh37	Chromosome 9, 80409488: 80409488
2	GNAQ	NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913492	GRCh38	Chromosome 9, 77794572: 77794572
3	GNAQ	NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913492	GRCh37	Chromosome 9, 80409488: 80409488
4	GNAQ	NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913492	GRCh38	Chromosome 9, 77794572: 77794572
5	GNA11	NM_002067.4(GNA11): c.626A> C (p.Gln209Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519742	GRCh37	Chromosome 19, 3118942: 3118942
6	GNA11	NM_002067.4(GNA11): c.626A> C (p.Gln209Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519742	GRCh38	Chromosome 19, 3118944: 3118944
7	GNA11	NM_002067.4(GNA11): c.626A> T (p.Gln209Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519742	GRCh37	Chromosome 19, 3118942: 3118942
8	GNA11	NM_002067.4(GNA11): c.626A> T (p.Gln209Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519742	GRCh38	Chromosome 19, 3118944: 3118944
9	GNAQ	NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu)	indel	Likely pathogenic	rs1057519853	GRCh37	Chromosome 9, 80409488: 80409489
10	GNAQ	NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu)	indel	Likely pathogenic	rs1057519853	GRCh38	Chromosome 9, 77794572: 77794573

Cosmic variations for Ocular Melanoma:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM52969	GNA11	eye,uveal tract,malignant melanoma,ring	c.626A>T	p.Q209L	19:3118944-3118944	0
2	COSM6498619	BAP1	eye,uveal tract,malignant melanoma,ring	c.306C>G	p.N102K	3:52408027-52408027	0

Sources

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Sources

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.69	CDKN2A GNA11 GNAQ NRAS VEGFA
2	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.49	GNAQ KIT NRAS VEGFA
3	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.43	GNA11 GNAQ NRAS VEGFA
4	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.4	BRCA2 CDKN2A KIT NRAS VEGFA
5	NF-kappaB Signaling ⁴	12.27	CIITA IL2 KIT MAGEA3
6	Pathways in cancer ³⁸	11.95	BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
7	UVA-Induced MAPK Signaling ⁶⁵ Show member pathways UVB-Induced MAPK Signaling ⁶⁵	11.8	GNA11 GNAQ NRAS
8	S1P3 pathway ¹ Show member pathways S1P1 pathway ¹ S1P2 pathway ¹ S1P4 pathway ¹ S1P5 pathway ¹ Sphingosine 1-phosphate (S1P) pathway ¹	11.71	GNA11 GNAQ VEGFA
9	Corticotropin-releasing hormone signaling pathway ¹	11.55	GNA11 GNAQ IL2
10	Gap junction ³⁸	11.44	GNA11 GNAQ NRAS
11	G-protein signaling_RhoA regulation pathway ²³	11.42	GNA11 GNAQ IL2 NRAS
12	Bladder cancer ¹ ³⁸	11.2	CDKN2A NRAS VEGFA
13	Transcription_Transcription factor Tubby signaling pathways ²³	10.96	GNA11 GNAQ NRAS
14	Long-term depression ³⁸	10.91	GNA11 GNAQ NRAS
15	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling ¹	10.81	GNAQ NRAS

Sources

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	action potential	GO:0001508	9.46	GNA11 GNAQ
2	G protein-coupled acetylcholine receptor signaling pathway	GO:0007213	9.43	GNA11 GNAQ
3	developmental pigmentation	GO:0048066	9.4	GNA11 KIT
4	somatic stem cell division	GO:0048103	9.37	CDKN2A KIT
5	phototransduction, visible light	GO:0007603	9.32	GNA11 GNAQ
6	entrainment of circadian clock	GO:0009649	9.26	GNA11 GNAQ
7	positive regulation of protein kinase C signaling	GO:0090037	9.16	MC1R VEGFA
8	positive regulation of endothelial cell proliferation	GO:0001938	9.13	NRAS PDCD6 VEGFA
9	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	8.8	IL2 KIT VEGFA

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.8	BAP1 BRCA2 CDKN2A CIITA GNAQ IL2
2	GTP binding	GO:0005525	9.56	CIITA GNA11 GNAQ NRAS
3	G-protein beta/gamma-subunit complex binding	GO:0031683	9.32	GNA11 GNAQ
4	guanyl nucleotide binding	GO:0019001	9.16	GNA11 GNAQ
5	type 2A serotonin receptor binding	GO:0031826	8.62	GNA11 GNAQ

Sources

Sources for Ocular Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia